Key Highlights
- Teleflex received FDA Biologics License Application approval for EZPLAZ Freeze Dried Plasma, the first such product ever licensed in the United States.
- The product is approved for adults with bleeding-related conditions requiring plasma coagulation factor replacement when other plasma products are unavailable.
- EZPLAZ uses a patented flexible plastic bag technology, unlike current Emergency Use Authorization products that rely on glass bottles.
- The product has a storage temperature range of 2 to 25 degrees Celsius, a 12-month shelf life, and can be reconstituted in about 1 to 2.5 minutes.
A First-of-Its-Kind Approval for Emergency Plasma Transfusion
Teleflex (NYSE:TFX) has received Biologics License Application approval from the FDA for EZPLAZ Freeze Dried Plasma, marking the first freeze dried plasma product ever licensed by the agency and the first biologics license for a blood component in the company's history. The product is approved for transfusion in adults with bleeding-related conditions requiring replacement of multiple plasma coagulation factors, including situations involving uncontrolled hemorrhage, when plasma is needed but other plasma products are not available.
Company leadership within Teleflex's global vascular and emergency medicine division described the approval as enabling plasma transfusion in situations where it is critically needed, including air and road ambulances, hospital settings, and battlefield environments, positioning EZPLAZ as a tool designed specifically for scenarios where traditional plasma logistics have historically fallen short.
Addressing Long-Standing Logistical Barriers in Trauma Care
Hemorrhage remains the leading cause of preventable death among both battlefield and civilian trauma patients, with plasma products playing a critical role in managing bleeding and coagulopathy through proteins that help clot blood. However, traditional plasma products have faced significant logistical and operational challenges in combat and prehospital settings, including requirements for freezers, thawing equipment, extended thawing periods, and post-thaw refrigeration needs that limit their practical deployment in emergency and remote environments.
EZPLAZ addresses several of these constraints directly, featuring a storage temperature range of 2 to 25 degrees Celsius, a 12-month shelf life, and a reconstitution time of approximately 1 to 2.5 minutes, characteristics that could meaningfully expand where and how quickly plasma can be administered compared with conventional frozen products. The product also utilizes a patented flexible plastic bag technology, differentiating it from current Emergency Use Authorization freeze dried plasma products that rely on glass bottle containers.
A Long-Running Defense Partnership Culminates in Regulatory Approval
The approval reflects an extended collaboration between Teleflex and the US Defense Health Agency, which identified the development of an FDA-approved, commercially available freeze dried plasma source as a top priority given the clinical challenges facing battlefield trauma care. A Teleflex subsidiary entered a Cooperative Research and Development Agreement with the agency's Warfighter Protection and Acute Care program back in April 2014, underscoring the multi-year timeline required to bring this type of biologics product through development and regulatory review.
A project manager within the defense program characterized the partnership as central to bringing shelf-stable, easy to transport blood products to frontline medical settings, while Teleflex's clinical safety leadership noted that the company's development program was specifically designed to generate the evidence needed to support the product's safety and effectiveness for its approved indication, crediting investigators, blood donors, and study participants for enabling the milestone.
Conclusion
Teleflex's FDA approval for EZPLAZ Freeze Dried Plasma represents a significant regulatory and clinical milestone, introducing the first licensed freeze dried plasma product in the United States after more than a decade of collaborative development with defense health authorities. By addressing longstanding logistical barriers tied to storage, thawing, and transport, the product could expand access to plasma transfusion capability across both military and civilian emergency settings where traditional frozen plasma has proven impractical, potentially influencing outcomes for hemorrhage patients in time-critical situations.






Please wait processing your request...